Uncategorized – Page 60 – Marius Grobler

What to know about the abortion pill under the Trump administration

Over time, the FDA reaffirmed mifepristone’s safety and repeatedly eased restrictions.
Many Americans wonder whether the pill used in most U.S. abortions will be restricted under the new Republican administration in Washington.

There’s no better time to apply for 2025 Brands That Matter

Apply before the end of the day on March 28 to get the Super Early rate.
The deadline to claim the Super Early rate for Fast Company’s Brands That Matter is this Friday. Rates go up March 28 at 11:59 p.m. ET.

U.S. Home-Price Accelerated in January, but Mortgage Rates Still Weighed

https://www.wsj.com/economy/housing/u-s-home-price-accelerated-in-january-but-mortgage-rates-still-weighed-ac5aaf40?siteid=yhoof2&yptr=yahoo

Mixer brand Three Cents to enter Hong Kong, Singapore

https://www.just-drinks.com/news/mixer-brand-three-cents-to-enter-hong-kong-singapore/

Honeywell Names Sewell as CEO of Advanced Materials Business

https://www.investopedia.com/honeywell-names-sewell-as-ceo-of-advanced-materials-business-11702777

Bitcoin’s $12B Quarterly Options Expiry Unlikely to Cause Major Market Reaction, Deribit Says

https://www.coindesk.com/markets/2025/03/25/tokenized-treasuries-hit-usd5b-milestone-as-fidelity-investments-touts-rwa-potential-as-collateral

Why Summit Therapeutics Stock Slipped Today

Summit Therapeutics (NASDAQ: SMMT) stock did better than a lot of other equities during an otherwise forgettable trading session on Wednesday. In contrast to other titles that fell notably, Summit more or less kept pace with the S&P 500 (SNPINDEX: ^GSPC), managing to dip by a relatively modest 2.25% in price. Some investors, at least, were cheered by an analyst’s recommendation upgrade on the stock.Well before market open, Citigroup pundit Yigal Nochomovitz changed his recommendation on Summit’s shares to buy from neutral. Accompanying this was a generous price target increase; the analyst’s fair value assessment is now $35 per share, where formerly it stood at $23. According to reports, Nochomovitz wrote that his move was based on a concentrated analysis of the prospects for ivonescimab. This is a rather promising cancer drug Summit has licensed from Chinese peer Akeso. The pundit feels that the coming readout of the medication’s Harmoni-2 late-stage clinical trial has a 70% chance of indicating a favorable result with overall survival rates. Continue readinghttps://www.fool.com/investing/2025/03/26/why-summit-therapeutics-stock-slipped-today/

Category: Uncategorized